Meet us next:   BIO International Convention 2025 – 4 September  ●  ELRIG – Drug Discovery in Scotland 2025 – 17 September  ●  The Cell & Gene Meeting on the Mesa 2025 – 6-8 October (in person) & 9-10 October (virtual)  ●  ELRIG – Drug Discovery – 21-22 October  ●  more on our events calendar
Prices for NutriStem, NutriCoat, and NutriFreez products will increase effective 1st August. Lock in the current price by getting your order by 31st July.

Recombinant human/ mouse/ rat follistatin-resistant activin A (FRACTA) protein

QK035

Brand: Qkine

Follistatin-resistant activin A (FRACTA) protein has been engineered to prevent binding to the natural inhibitor, follistatin. In vivo activin A activity is regulated by follistatin, a high-affinity inhibitor; follistatin accumulates in stem cell culture, where it inhibits activin A.

Qk035 follistatin-resistant activin A (FRACTA) has equivalent bioactivity to wild-type activin A (Qk001) but does not bind follistatin so is resistant to feedback inhibition. High purity 26 kDa dimer comprising engineered mature domain of activin A protein, animal origin-free (AOF) and carrier-protein free (CF). This specialised activin A has been developed in Marko Hyvönen’s group in the University of Cambridge.

Currency: 

Product name Catalog number Pack size Price Price (USD) Price (GBP) Price (EUR)
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 25 µg QK035-0025 25 µg (select above) $ 280.00 £ 205.00 € 240.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 50 µg QK035-0050 50 µg (select above) $ 410.00 £ 305.00 € 357.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 100 µg QK035-0100 100 µg (select above) $ 620.00 £ 455.00 € 532.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 500 µg QK035-0500 500 µg (select above) $ 2,500.00 £ 1,840.00 € 2,150.00
Recombinant human/mouse/rat follistatin-resistant activin A (FRACTA) protein, 1000 µg QK035-1000 1000 µg (select above) $ 3,950.00 £ 2,900.00 € 3,388.00

Note: prices shown do not include shipping and handling charges.

Qkine company name and logo are the property of Qkine Ltd. UK.

Alternative protein names
ActA, Activin beta-A chain, Erythroid differentiation protein (EDP), Follicle-Stimulating Hormone (FSH) releasing protein (FRP), INHBA, Inhibin beta A, Inhibin beta 1
Species reactivity

human

species similarity:
mouse – 98%
rat – 98%
porcine – 98%
bovine – 98%

Frequently used together:

Summary

  • High purity mature domain of follistatin-resistant activin A protein
  • >98%, by SDS-PAGE quantitative densitometry
  • 26 kDa (dimer)
  • Expressed in E. coli
  • Animal origin-free (AOF) and carrier protein-free.
  • Manufactured in Qkine's Cambridge, UK laboratories
  • Lyophilized from acetonitrile, TFA
  • Resuspend in 10 mM HCl at >100 µg/ml (provided with protein and free of charge), prepare single use aliquots, add carrier protein if desired and store frozen at -20°C or -80°C
Handling and Storage FAQ

Featured applications

  • Induced pluripotent and embryonic stem cell differentiation and maintenance

Bioactivity

follistatin resistant activin A Qk035 protein bioactivity lot #104287

Activin A protein activity is determined using an activin-responsive firefly luciferase reporter in HEK293T cells.  EC50 for wild-type activin A (Qk001) = 0.228 ng/ml (8.776 pM), EC50 for follistatin-resistant activin A (FRACTA, Qk035) = 0.228 ng/ml (8.792 pM).

Purity

follistatin resistant activin A FRACTA Qk035 protein purity lot #104287

FRACTA migrates as a single band at 24 kDa in non-reducing (NR) and 13 kDa as a single monomeric species upon reduction (R).  No contaminating protein bands are visible. Purified recombinant protein (1 µg) was resolved using 15% w/v SDS-PAGE in reduced (+β-mercaptothanol, R) and non-reduced conditions (NR) and stained with Coomassie Brilliant Blue R250.  Data from Qk035 lot #104287.

Further quality assays

  • Mass spectrometry: single species with expected mass
  • Analytical reversed-phase: single sharp peak
  • Endotoxin: <0.005 EU/μg protein (below level of detection)
  • Recovery from stock vial:  >95%

Protein background

Human activin A protein is a member of the TGF-β superfamily of growth factors involved in stem cell differentiation and maintenance, regulation of embryogenesis, development of the reproductive system, wound healing and regulation of immune responses.  Activin A signaling is modulated by the glycoprotein follistatin, production is which is stimulated by activin A forming a feedback loop [1], and inhibins.

Follistatin binds to and neutralises members of the TGF-β superfamily, preventing signalling by shielding the type II and I receptor binding sites [2-4].

Activins are disulfide-linked homo- and heterodimers of four inhibin β chains. The best characterized are activin A and activin B, homodimers of inhibin βA and inhibin βB respectively. Activins, like all other members in the TGF-β superfamily, are synthesized as larger precursors consisting of an N-terminal signal peptide, a pro-domain of 250–350 residues and a highly conserved mature domain. The pro-domain, which is cleaved off in the mature protein, has important roles in the biosynthesis, stabilization, transportation and signalling of the growth factors [5].

Recombinant activin A is used for maintenance of pluripotency in many human induced-pluripotent stem cell and human embryonic stem cell lines [3], and to induce stem cell differentiation into endoderm [6] and other cell fates.

Follistatin resistant activin A (FRACTA) has been developed in the lab of Marko Hyvönen at the University of Cambridge. FRACTA has been engineered to be unimpeded by follistatin while maintaining its ability to bind type I and II receptors.

negative feedback inhibition of activin A by follistatin

Background references

  1. Harrington, A. E. et al. Structural basis for the inhibition of activin signalling by follistatin. EMBO J. 25, 1035–1045 (2006). doi.org/10.1038/sj.emboj.7601000
  2. Wang, X., Fischer, G. & Hyvönen, M. Structure and activation of pro-activin A. (2016). doi:10.1038/ncomms12052
  3. Jones, K. L., Kretser, D. M. de, Patella, Shane. & Phillips, D. J. Activin A and follistatin in systemic inflammation. Molecular and Cellular Endocrinology 225, 119–125 (2004). doi.org/10.1016/j.mce.2004.07.010
  4. Walton, K. L., Makanji, Y. & Harrison, C. A. New insights into the mechanisms of activin action and inhibition. Molecular and Cellular Endocrinology 359, 2–12 (2012). doi.org/10.1016/j.mce.2011.06.030
  5. Pauklin, S. & Vallier, L. Activin/Nodal signalling in stem cells. Development 142, 607–19 (2015). doi.org/10.1242/dev.091769
  6. D’Amour, K. A. et al. Efficient differentiation of human embryonic stem cells to definitive endoderm. Nat. Biotechnol. 23, 1534–1541 (2005). doi.org/10.1038/nbt1163